All Stories

  1. Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair

    Article • Pharmacological Reviews, November 2024, Elsevier

    Dr. Ron Milo

  2. The consequences of switching from Gilenya® to generics for fingolimod

    Article • Multiple Sclerosis and Related Disorders, June 2023, Elsevier

    Dr. Ron Milo

  3. B cell targeted therapies in inflammatory autoimmune disease of the central nervous system

    Article • Frontiers in Immunology, March 2023, Frontiers

    Dr. Ron Milo

  4. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals

    Article • Multiple Sclerosis and Related Disorders, May 2021, Elsevier

    Dr. Ron Milo

  5. The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5

    Article • Nature Communications, March 2021, Springer Science + Business Media

    Dr. Ron Milo

  6. Association between cervical disc disease and lesions of multiple sclerosis

    Article • The Neuroradiology Journal, January 2021, SAGE Publications

    Dr. Ron Milo

  7. EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis

    Article • Journal of Palliative Medicine, November 2020, Mary Ann Liebert Inc

    Dr. Ron Milo, Professor Ivan G. Milanov, Dr. Alessandra Solari

  8. Ofatumumab versus Teriflunomide in Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2020, New England Journal of Medicine (NEJM/MMS)

    Dr Pedro Jesus Serrano-Castro, Dr. Ron Milo, Professor Tjalf Ziemssen

  9. EAN guideline on palliative care of people with severe, progressive multiple sclerosis

    Article • European Journal of Neurology, May 2020, Wiley

    Dr. Alessandra Solari, Dr. Ron Milo, Professor Ivan G. Milanov

  10. Familial Creutzfeldt–Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course

    Article • Deutsche Zeitschrift für Nervenheilkunde, May 2020, Springer Science + Business Media

    Dr. Ron Milo

  11. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis

    Article • European Journal of Neurology, February 2020, Wiley

    Dr. Ron Milo

  12. Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis

    Article • European Neurological Review, January 2020, Touch Digital Media, Ltd.

    Dr. Ron Milo

  13. The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis

    Article • Multiple Sclerosis Journal, November 2019, SAGE Publications

    Dr. Ron Milo

  14. Immunological Aspects of Approved MS Therapeutics

    Article • Frontiers in Immunology, July 2019, Frontiers

    Dr. Ron Milo

  15. B Cell-based Therapies for Multiple Sclerosis

    Article • June 2019, Royal Society of Chemistry

    Dr. Ron Milo

  16. Therapies for multiple sclerosis targeting B cells

    Article • Croatian Medical Journal, April 2019, Croatian Medical Journal

    Dr. Ron Milo

  17. A retrospective analysis of the development of seizure frequency in patients with seizures during a period of military conflict

    Article • Seizure, October 2018, Elsevier

    Dr. Ron Milo

  18. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis

    Article • Expert Review of Clinical Pharmacology, August 2017, Taylor & Francis

    Dr. Ron Milo

  19. Spotlight on daclizumab: its potential in the treatment of multiple sclerosis

    Article • Degenerative Neurological and Neuromuscular Disease, November 2016, Dove Medical Press

    Dr. Ron Milo

  20. Therapeutic strategies targeting B-cells in multiple sclerosis

    Article • Autoimmunity Reviews, July 2016, Elsevier

    Dr. Ron Milo

  21. Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs

    Article • Expert Opinion on Pharmacotherapy, January 2015, Informa Healthcare

    Dr. Ron Milo

  22. Revised diagnostic criteria of multiple sclerosis

    Article • Autoimmunity Reviews, April 2014, Elsevier

    Dr. Ron Milo

  23. The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis

    Article • Therapeutic Advances in Neurological Disorders, September 2013, SAGE Publications

    Dr. Ron Milo

  24. Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis

    Article • Archives of Neurology, October 2012, American Medical Association (AMA)

    Dr. Ron Milo, Prof Roy G Beran

  25. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2012, New England Journal of Medicine (NEJM/MMS)

    Dr. Ron Milo

  26. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

    Article • The Lancet Neurology, May 2012, Elsevier

    Dr. Ron Milo, Prof Roy G Beran

  27. Stroke in the Very Elderly: Characteristics and Outcome in Patients Aged =85 Years with a First-Ever Ischemic Stroke

    Article • Neuroepidemiology, January 2012, Karger Publishers

    Dr. Ron Milo

  28. The increasing incidence and prevalence of female multiple sclerosis—A critical analysis of potential environmental factors

    Article • Autoimmunity Reviews, June 2011, Elsevier

    Dr. Ron Milo

  29. Multiple sclerosis and chronic cerebrospinal venous insufficiency: a critical review

    Article • Therapeutic Advances in Neurological Disorders, May 2011, SAGE Publications

    Dr. Ron Milo

  30. In Memoriam: Hillel S. Panitch, MD (1940-2010)

    Article • Archives of Neurology, May 2011, American Medical Association (AMA)

    Dr. Ron Milo

  31. High prevalence of malignant melanoma in Israeli patients with Parkinson’s disease

    Article • Journal of Neural Transmission, February 2011, Springer Science + Business Media

    Dr. Ron Milo

  32. Combination therapy in multiple sclerosis

    Article • Journal of Neuroimmunology, February 2011, Elsevier

    Dr. Ron Milo

  33. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis

    Article • Annals of Neurology, January 2011, Wiley

    Dr. Ron Milo

  34. Tau and 14-3-3 of genetic and sporadic Creutzfeldt–Jakob disease patients in Israel

    Article • Deutsche Zeitschrift für Nervenheilkunde, September 2010, Springer Science + Business Media

    Dr. Ron Milo

  35. Translational Research in Neurology and Neuroscience 2010

    Article • Archives of Neurology, July 2010, American Medical Association (AMA)

    Dr. Ron Milo

  36. Multiple sclerosis: Geoepidemiology, genetics and the environment

    Article • Autoimmunity Reviews, March 2010, Elsevier

    Dr. Ron Milo

  37. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2010, New England Journal of Medicine (NEJM/MMS)

    Dr. Ron Milo, Prof Roy G Beran

  38. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke

    Article • Stroke, November 2009, Wolters Kluwer Health

    Dr. Ron Milo

  39. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

    Article • The Lancet Neurology, October 2009, Elsevier

    Dr. Ron Milo

  40. Local corticosteroid treatment for carpal tunnel syndrome: A 6-month clinical and electrophysiological follow-up study

    Article • Journal of Back and Musculoskeletal Rehabilitation, June 2009, IOS Press

    Dr. Ron Milo

  41. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial

    Article • The Lancet, December 2008, Elsevier

    Professor Malcolm R Macleod, Alba Piroli, Professor David Torgerson, Dr. Ron Milo

  42. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PR...

    Article • The Lancet Neurology, October 2008, Elsevier

    Dr. Ron Milo, Prof. Dr. Otto W. Witte, Director of the stroke unit, DMSci, clinical research associate professor Helle K. Iversen

  43. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2008, New England Journal of Medicine (NEJM/MMS)

    Dr. Ron Milo, Prof. Dr. Otto W. Witte, Director of the stroke unit, DMSci, clinical research associate professor Helle K. Iversen

  44. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2008, New England Journal of Medicine (NEJM/MMS)

    Dr. Ron Milo, Prof. Dr. Otto W. Witte, Director of the stroke unit, DMSci, clinical research associate professor Helle K. Iversen

  45. Multiple Sclerosis

    Article • January 2008, Springer Science + Business Media

    Dr. Ron Milo

  46. The utility of the Visual Analogue Scale for the assessment of depressive mood in cognitively impaired patients

    Article • International Journal of Geriatric Psychiatry, July 2004, Wiley

    Prof ABRAHAM WEIZMAN, Dr. Ron Milo

  47. The Myelin-Associated Oligodendrocytic Basic Protein Region MOBP15–36 Encompasses the Immunodominant Major Encephalitogenic Epitope(s) for SJL/J Mice and Predicted Epitope(s) for Multiple Sclerosis-Associated HLA-DRB1*1501

    Article • The Journal of Immunology, July 2004, The American Association of Immunologists

    Dr. Ron Milo

  48. Neurological features of West Nile Virus infection during the 2000 outbreak in a regional hospital in Israel

    Article • Journal of the Neurological Sciences, August 2002, Elsevier

    Dr. Ron Milo

  49. Bilateral vestibular failure as a unique presenting sign in carcinomatous meningitis: case report

    Article • Journal of Neurology Neurosurgery & Psychiatry, May 2001, BMJ

    Dr. Ron Milo

  50. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases

    Article • Annals of the Rheumatic Diseases, January 2000, BMJ

    Dr. Ron Milo

  51. Glatiramer Acetate or Interferon-?? for Multiple Sclerosis?

    Article • CNS Drugs, January 1999, Springer Science + Business Media

    Dr. Ron Milo

  52. Effect of Propranolol and IFN-β on the Induction of MHC Class II Expression and Cytokine Production by IFN-γ in THP-1 Human Monocytic Cells

    Article • Immunopharmacology and Immunotoxicology, January 1998, Taylor & Francis

    Dr. Ron Milo

  53. Glatiramer acetate blocks the activation of THP-1 cells by interferon-γ

    Article • European Journal of Pharmacology, January 1998, Elsevier

    Dr. Ron Milo

  54. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions

    Article • European Journal of Immunology, November 1997, Wiley

    Dr. Ron Milo

  55. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial

    Article • Neurology, December 1996, Wolters Kluwer Health

    Dr. Ron Milo

  56. Additive effects of copolymer-1 and interferon β-1b on the immune response to myelin basic protein

    Article • Journal of Neuroimmunology, September 1995, Elsevier

    Dr. Ron Milo

  57. Interferon β-lb reduces Interferon γ-induced antigen-presenting capacity of human glial and B cells

    Article • Journal of Neuroimmunology, August 1995, Elsevier

    Dr. Ron Milo

  58. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

    Article • Journal of Clinical Investigation, December 1993, American Society for Clinical Investigation

    Dr. Ron Milo

  59. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

    Article • Proceedings of the National Academy of Sciences, January 1992, Proceedings of the National Academy of Sciences

    Dr. Ron Milo

  60. Specific inhibition by the synthetic copolymer COP-1 of human T cell lines specific to myelin basic protein

    Article • Journal of Neuroimmunology, January 1991, Elsevier

    Dr. Ron Milo

  61. Tiapride as Treatment for Certain Patients with Idiopathic Torsion Dystonia

    Article • European Neurology, January 1991, Karger Publishers

    Dr. Ron Milo

  62. Delayed epidural hematoma a review

    Article • Acta Neurochirurgica, March 1987, Springer Science + Business Media

    Dr. Ron Milo

  63. Purulent meningitis due to Pseudomonas aeruginosa successfully treated with colistin and piperacillin

    Article • Journal of Infection, November 1985, Elsevier

    Dr. Ron Milo